Therefore, further analysis of the correlation between HSP90B1 and PD1 in BLCA may help us better understand the potential of HSP90B1 in BLCA immunotherapy (Figure 9A). This evidence concerns the gene HSP90B1 and bladder transitional cell carcinoma.